Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Ferrixan' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Ferrixan' found in 1 term [] and 1 definition []
1 - 2 (of 2)     
Result Pages : [1]
MRI Resources 
Examinations - Safety Training - Claustrophobia - PACS - Contrast Enhanced MRI - Pacemaker
 
FerrixanInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
spacer
 
• Share the entry 'Ferrixan':  Facebook  Twitter  LinkedIn  
MRI Resources 
Shoulder MRI - MRI Technician and Technologist Jobs - - PACS - Developers - Shielding
 
Resovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Resovist® is an organ-specific MRI contrast agent, used for the detection and characterization of especially small focal liver lesions.
Resovist® consists of superparamagnetic iron oxide (SPIO) nanoparticles coated with carboxydextran, which are accumulated by phagocytosis in cells of the reticuloendothelial system (RES) of the liver. The uptake of Resovist® Injection in the reticuloendothelial cells results in a decrease of the signal intensity of normal liver parenchyma on both T2- and T1 weighted images.
Most malignant liver tumors do not contain RES cells and therefore do not uptake the iron particles. The resulting imaging effect is an improved contrast between the tumor (bright) and the surrounding tissue (dark).
Resovist® can be injected as an intravenous bolus, which allows immediate imaging of the liver and reduces the overall examination time. A dynamic imaging strategy after bolus injection supports to characterize lesions. In comprehensive clinical trials, it demonstrated an excellent safety profile.
In 2001, Resovist® was approved for the European market.

See also Superparamagnetic Iron Oxide.

Resovist® competed with Primovist™, the other liver imaging agent of Bayer Schering Pharma AG. Due to this reason, the production of Resovist® has been abandoned in 2009.
Drug Information and Specification
NAME OF COMPOUND
Ferrixan [Ferucarbotran], carboxydextran coated iron oxide nanoparticles
CENTRAL MOIETY
Fe2+
CONTRAST EFFECT
T2/T1, Predominantly negative enhancement
r1=25.4, r2=151,
PHARMACOKINETIC
RES-directed
333 mosm/kg
CONCENTRATION
0.5 mol Fe/L
DOSAGE
Less than 60 kg = 0.9 ml, greater than 60 kg = 1.4 ml
PREPARATION
Finished product
INDICATION
Liver lesions
DISTRIBUTOR
See below
PRESENTATION
Pre-filled syringes of 0.9 and 1.4 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
Resovist®
?
-
Japan
Resovist®
approved
-
EU
Resovist®
approved
-
Australia
Resovist®
Approved
-
spacer

• View the DATABASE results for 'Resovist®' (6).Open this link in a new window

 
Further Reading:
  News & More:
Optimized Labelling of Human Monocytes with Iron Oxide MR Contrast Agents
Sunday, 30 November 2003   by rsna2003.rsna.org    
MRI Resources 
Resources - Directories - NMR - Shoulder MRI - Health - Cardiovascular Imaging
 
     1 - 2 (of 2)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



Personalized protocols (age, gender, body habitus, etc.) lead to :
more automated planning 
improved patient comfort 
better diagnostics 
optimized image quality 
nothing 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 29 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]